Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Review

Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives

Authors: Jing Liu, Shuo Pan, Xiqiang Wang, Zhongwei Liu, Yong Zhang

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

In diabetic metabolic disorders, advanced glycation end products (AGEs) contribute significantly to the development of cardiovascular diseases (CVD).

Aims

This comprehensive review aims to elucidate the molecular mechanisms underlying AGE-mediated vascular injury.

Conclusions

We discuss the formation and accumulation of AGEs, their interactions with cellular receptors, and the subsequent activation of signaling pathways leading to oxidative stress, inflammation, endothelial dysfunction, smooth muscle cell proliferation, extracellular matrix remodeling, and impaired angiogenesis. Moreover, we explore potential therapeutic strategies targeting AGEs and related pathways for CVD prevention and treatment in diabetic metabolic disorders. Finally, we address current challenges and future directions in the field, emphasizing the importance of understanding the molecular links between AGEs and vascular injury to improve patient outcomes.
Literature
1.
Diagnosis and classification of diabetes mellitus. Diabetes Care, 2013. 36(Suppl 1): S67–74.
2.
Shah AD, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–13.PubMedPubMedCentralCrossRef
3.
4.
Goldin A, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605.PubMedCrossRef
5.
Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93(4):1143–52.PubMedCrossRef
6.
Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196(1):9–21.PubMedCrossRef
7.
Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11(18):2279–99.PubMedCrossRef
8.
Perrone A, et al. Advanced glycation end products (AGEs): biochemistry, signaling, analytical methods, and epigenetic effects. Oxid Med Cell Longev. 2020;2020:3818196.PubMedPubMedCentralCrossRef
9.
Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–57.PubMedCrossRef
10.
11.
Ahmed N. Advanced glycation endproducts–role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3–21.PubMedCrossRef
12.
Rabbani N, Xue M, Thornalley PJ. Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments. Clin Sci (Lond). 2016;130(19):1677–96.PubMedCrossRef
13.
Vistoli G, et al. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res. 2013;47(Suppl 1):3–27.PubMedCrossRef
14.
Uribarri J, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911-16.e12.PubMedPubMedCentralCrossRef
15.
Takeuchi M, et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease. Curr Alzheimer Res. 2004;1(1):39–46.PubMedCrossRef
16.
Gugliucci A, Menini T. The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease. Adv Exp Med Biol. 2014;824:191–208.PubMedCrossRef
17.
Baynes JW. The role of AGEs in aging: causation or correlation. Exp Gerontol. 2001;36(9):1527–37.PubMedCrossRef
18.
Ramasamy R, et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005;15(7):16r–28r.PubMedCrossRef
19.
Basta G, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105(7):816–22.PubMedCrossRef
20.
21.
Ohgami N, et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci. 2001;947:350–5.PubMedCrossRef
22.
Vlassara H, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995;1(6):634–46.PubMedPubMedCentralCrossRef
23.
24.
Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21(2):79–85.PubMedCrossRef
25.
26.
27.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.PubMedCrossRef
28.
Nieuwdorp M, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006;55(4):1127–32.PubMedCrossRef
29.
Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017;9(5):434–49.PubMedCrossRef
30.
Yuan G, et al. Advanced glycation end products induce proliferation and migration of human aortic smooth muscle cells through PI3K/AKT pathway. Biomed Res Int. 2020;2020:8607418.PubMedPubMedCentralCrossRef
31.
32.
Monnier VM, et al. Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications. Clin Chem Lab Med. 2014;52(1):21–32.PubMedPubMedCentralCrossRef
33.
Yamagishi SI, Matsui T. Role of ligands of receptor for advanced glycation end products (RAGE) in peripheral artery disease. Rejuvenation Res. 2018;21(5):456–63.PubMedCrossRef
34.
Forbes JM, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14(8 Suppl 3):S254–8.PubMedCrossRef
35.
Wendt TM, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162(4):1123–37.PubMedPubMedCentralCrossRef
36.
37.
Barile GR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46(8):2916–24.PubMedCrossRef
38.
Huang JS, et al. Cinnamaldehyde and nitric oxide attenuate advanced glycation end products-induced the Jak/STAT signaling in human renal tubular cells. J Cell Biochem. 2015;116(6):1028–38.PubMedCrossRef
39.
Freedman BI, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999;20(5):493–510.PubMedCrossRef
40.
Onorato JM, et al. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions Mechanism of action of pyridoxamine. J Biol Chem. 2000;275(28):21177–84.PubMedCrossRef
41.
Williams ME, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27(6):605–14.PubMedCrossRef
42.
Bucciarelli LG, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106(22):2827–35.PubMedCrossRef
43.
44.
Nonaka K, et al. Advanced glycation end-products increase IL-6 and ICAM-1 expression via RAGE, MAPK and NF-κB pathways in human gingival fibroblasts. J Periodontal Res. 2018;53(3):334–44.PubMedCrossRef
45.
Xu Y, et al. Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation. Int Immunopharmacol. 2010;10(12):1552–9.PubMedCrossRef
46.
Heydari AH, et al. Advanced glycation end product blocker drugs have a great potential to prevent diabetic cardiomyopathy in an animal model of diabetes mellitus type-2. Cardiovasc Ther. 2022;2022:7014680.PubMedPubMedCentralCrossRef
47.
Cuzzocrea S, et al. Effects of n-acetylcysteine in a rat model of ischemia and reperfusion injury. Cardiovasc Res. 2000;47(3):537–48.PubMedCrossRef
48.
Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004;173(1):1–12.PubMedCrossRef
49.
Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–53.PubMedCrossRef
50.
51.
Meerwaldt R, et al. Clinical relevance of advanced glycation endproducts for vascular surgery. Eur J Vasc Endovasc Surg. 2008;36(2):125–31.PubMedCrossRef
52.
Mulik RS, et al. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm. 2010;7(3):815–25.PubMedCrossRef
53.
54.
Schalkwijk CG, Stehouwer CDA. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. Physiol Rev. 2020;100(1):407–61.PubMedCrossRef
55.
Pena MJ, et al. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes Obes Metab. 2017;19(5):749–53.PubMedCrossRef
56.
La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol. 2019;26(2_suppl):15–24.PubMedCrossRef
Metadata
Title
Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives
Authors
Jing Liu
Shuo Pan
Xiqiang Wang
Zhongwei Liu
Yong Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01431-w

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy

Research

Aldosterone inhibits Dot1l expression in guinea pig cochlea

Review

Role of regulatory T cells in spinal cord injury

Research

Altered glycosylation profiles of serum IgG in Takayasu arteritis

Research

Sleep disturbance increases the risk of severity and acquisition of COVID-19: a systematic review and meta-analysis

Research

What should we expect when two myositis-specific antibodies coexist in a patient